Read This First
This page is not built on clinical evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the regulatory record and the trial registry, and for this compound both changed in 2026.
MOTS-c has no list price, no prescription route, no insurance pathway and no manufacturer, because it is not approved anywhere, no controlled trial of the peptide itself has reported, and it is not on the list of substances pharmacies may compound.1 It does have, unusually for this corner of the library, a Phase 2 trial recruiting and a favourable advisory vote. Neither is a price.
This page publishes no prices. What follows is what determines the money.
Why There Is No Price
What a Price Normally Represents
For an approved medicine, a price sits on top of a known quantity of a known substance, made to a validated standard, for a stated indication, with a documented effect. For MOTS-c, the substance is known, the quantity is unverified, there is no standard, and the effect in humans has not been measured. What exists is a strong mouse literature and one human trial of a different molecule whose sponsor could not formulate it.23
What Is Different About This Compound's Economics?
The delivery question. Most unapproved peptides are sold on the hope that they do in people what they did in animals. MOTS-c carries an extra uncertainty in front of that one: whether the peptide, injected under the skin, survives long enough to do anything at all. Human blood hydrolyses it within minutes in vitro, and the FDA said it is "unclear whether exogenous administration" by that route "can generate pharmacologically active concentrations."1
A buyer is therefore paying for two unknowns stacked: whether the molecule works in humans, and whether the product delivers the molecule. The company best placed to solve the second, founded by the peptide's discoverer, spent years and a Phase 1b on it and stopped.3
Access
Is There a Legal Route?
One, and it is not a purchase. A Phase 2 trial of MOTS-c in 120 adults with prediabetes and overweight or obesity has been recruiting since February 2026, randomised, double-blind and placebo-controlled, with insulin sensitivity as its primary endpoint and completion estimated for 2028.4 Trial participation is not a way of getting the drug cheaply: participants may receive placebo, must meet eligibility criteria, and take on trial obligations. It is a legitimate route with the trade-offs of a trial rather than the terms of a purchase, and it is the only way to receive MOTS-c under any form of oversight.
What Did the July 2026 Vote Do?
On 23 July 2026 the FDA's advisory committee voted 7 to 5, with two abstentions, to recommend MOTS-c for the 503A bulks list for obesity and osteoporosis, over the FDA's objection that it was not well characterised and had no human safety or effectiveness data.51 The recommendation is advisory, the list can only be amended by rulemaking, and the FDA has not begun one. The nomination was for a subcutaneous injection at 5 and 10 mg, so if the FDA does act, the compounded product would resemble what is sold now, on prescription, from pharmacies that would first have to find characterised material.1
Until then, no pharmacy in the United States has a lawful basis on which to compound it.
Does Insurance Cover It?
No, and there is nothing to appeal. Payers reimburse approved products for approved indications. A compounded product on a bulks list, if it ever exists, would still not be an approved drug, and compounded preparations generally fall outside pharmacy benefit coverage.
Can HSA or FSA Funds Be Used?
Tax-advantaged health accounts cover qualified medical expenses, which generally requires a legitimate medical purpose and often a provider's documentation. A product that cannot lawfully be dispensed for human use sits poorly against that. The account holder carries the consequences of a disallowed expense; the question belongs with the plan administrator.
What the Money Buys
Where Does the Spread Between Sellers Come From?
| Cost component | Present in | What it buys |
|---|---|---|
| Consultation and clinician time | Clinics, telehealth | A history, an examination, a record, and someone accountable |
| Premises, staff and liability | Clinics | Overhead and recourse, not product |
| Bundling into a "longevity" or "metabolic" protocol | Clinics, vendors | Other compounds priced together so none is examined alone |
| Cold-chain shipping | Some vendors | The one component that addresses a real property of this peptide, if it is actually done; the only stability claim on record is a freezer1 |
| Marketing and affiliate commission | All channels, often invisible | Nothing for the buyer |
| The compound itself | All channels | Raw material of unverified identity, at a cost small relative to the components above it. ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown |
None of the spread buys verified product quality, because no channel offers that. A higher price buys service and accountability where those exist. For MOTS-c specifically, a higher price that includes genuine cold-chain handling buys something the cheaper option does not; whether it buys a peptide that survives injection is a question no price can answer.
The Spending Decision
What Result Is Being Paid For?
The product copy promises the effects of exercise, better insulin sensitivity, fat loss and longevity. In mice, MOTS-c prevented diet-induced obesity and insulin resistance and, started late in life, extended healthspan.62 In humans, the body's own MOTS-c rises with exercise, and a genetic variant that weakens it is associated with diabetes in sedentary men.7 That is a coherent and genuinely interesting story. It has not yet included an injection into a person that changed anything measurable.
The closest thing, CB4211, produced encouraging biomarker changes in a four-week Phase 1b that was never published and whose formulation was then abandoned.83
The honest description of a MOTS-c purchase in 2026 is a bet on the outcome of a trial that will not report until 2028, placed with a product that may not deliver the molecule the trial is testing.
What Is the Risk Side of the Ledger?
Probably low for the peptide itself, which every human cell makes, and unmeasured for the product. The FDA found no toxicity studies, no pharmacokinetics and no human exposure data, and its concern was immunogenicity from aggregation and impurities in an injectable.1 The genetic data hint that the peptide's effects may differ by sex, which no product page mentions.7 And it is listed as prohibited in the Global DRO database, which for a tested athlete is a cost that dwarfs the vial.1
What Should Be Asked Before Paying?
How was this stored and shipped, and at what temperature? The only stability claim on record is a freezer.
Which human study of MOTS-c itself measured the outcome you are promising? The honest answer is that the first one is recruiting.
Are you aware the July 2026 recommendation has not been adopted by the FDA, and on what legal basis are you supplying this?
Can I see a certificate for the batch I will receive, with endotoxin and microbial results?
Does anyone here earn commission on product sales?
What Would Change This Page
The Phase 2, or the FDA's Decision
The Hudson Biotech trial is the event that matters. A positive result in 2028 would be the first human evidence for the peptide and would settle the delivery question; a negative one would settle it the other way.4 The FDA's action on the July 2026 recommendation, whichever way it goes, would change the access position in the meantime. The ONPEPS July 2026 article covers the possible routes and their timescales.
A Note on "Cheaper Than a GLP-1"
The comparison circulates and it is not a comparison. Semaglutide and tirzepatide have documented effect sizes in tens of thousands of patients, list prices, and coverage. MOTS-c has a mouse literature and a trial that has not reported. A price ratio between them says nothing about value, because the denominator has no measured human effect to divide by. ONPEPS does not make it.
Related ONPEPS Coverage
MOTS-c library entry: the mouse data, the genetic evidence and the analogue that stalled
MOTS-c sourcing and quality: a peptide that blood destroys in minutes
FDA peptide news July 2026: the votes, the dissent and what happens next
Sources
US Food and Drug Administration. MOTS-c-related bulk drug substances (MOTS-c (free base) and MOTS-c acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 23 July 2026. Docket FDA-2025-N-6895. fda.gov
Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. Open access. pubmed.ncbi.nlm.nih.gov/33473109
CohBar, Inc. Form 10-Q for the quarter ended March 31, 2023, filed 11 May 2023. sec.gov
ClinicalTrials.gov. NCT07505745. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. Sponsor Hudson Biotech. Phase 2, recruiting. Record retrieved 16 September 2026. clinicaltrials.gov/study/NCT07505745
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 7 to 5 vote with two abstentions on MOTS-c. onpeps.com
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. Open access. pubmed.ncbi.nlm.nih.gov/25738459
Zempo H, Kim SJ, Fuku N, Nishida Y, Higaki Y, Wan J, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. Open access. pubmed.ncbi.nlm.nih.gov/33468709
CohBar, Inc. CohBar announces positive topline results from the Phase 1a/1b study of CB4211 under development for NASH and obesity. Press release, 10 August 2021. Company topline announcement; not peer reviewed. globenewswire.com
Not Medical or Financial Advice
MOTS-c is not approved for human use in any jurisdiction and no controlled trial of it has reported. Treatment decisions belong with a qualified healthcare provider. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what is known about what the money would be spent on.
Sources verified 16 September 2026. The Phase 2 result and the FDA's action on the July 2026 recommendation would each change parts of this page. Re-verify before relying on anything here.